NMS Labs
200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com
Robert A Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

CONFIDENTIAL

Demo Report

Report Issued 09/09/2011 15:01
Last Report Issued 09/09/2010 10:31

88888
Clinical Dummy reports
Attn: IT Department
200 Welsh Road
Horsham, PA 19044-2208

Patient Name 2148B-POS
Patient ID 2148B-POS
Chain 10001748
Age Not Given **Gender** Not Given

Workorder 10001748

Received 09/09/2010 10:27

Sample ID 10001748-001
Matrix Blood
Patient Name 2148B-POS
Patient ID 2148B-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
2148B Galantamine, Blood				
Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)				
Galantamine	5.0	ng/mL	1.0	
Synonym(s): Galanthamine; Lycoremine; NSC-100058; Razadyne®; Razadyne ER®				
Following a single 4 mg dose of the immediate-release tablet, mean peak plasma concentrations were reported to range from 16 - 28 ng/mL (within about 2 hours).				
Following a single 8 mg dose of the immediate-release tablet, mean peak plasma concentrations were reported to range from 39 - 56 ng/mL (within about 2 hours).				
Steady-state mean peak plasma concentrations using the 16 mg extended-release capsule were reported to range from 43 - 62 ng/mL (at a peak time of 3.5 - 5.7 hours).				
The blood to plasma concentration ratio for galantamine is 1.2.				